FDA Approves Oral Ensitrelvir for COVID-19 Post-Exposure Prophylaxis (PEP)

The U.S. Food and Drug Administration (FDA) has approved ensitrelvir, an oral antiviral medication, for use as post-exposure prophylaxis (PEP) against COVID-19 in high-risk individuals. The decision marks a significant expansion of treatment options for preventing severe illness after exposure to the virus, particularly as global cases rise amid new variants. Developed by Shionogi & Co., ensitrelvir joins a shrinking but critical arsenal of antiviral tools as the pandemic enters a new phase.

Unlike other COVID-19 antivirals, which primarily target the viral protease or polymerase, ensitrelvir works by inhibiting the 3CL protease, an enzyme essential for viral replication. The FDA’s approval follows clinical trials demonstrating a 77% reduction in symptomatic infection when taken within four days of exposure, according to data submitted by Shionogi and reviewed by the agency’s Antiviral Drugs Advisory Committee. The drug is now authorized for adults and pediatric patients aged 12 and older weighing at least 40 kilograms (88 pounds).

Dr. Patricia Keegan, director of the FDA’s Office of Antimicrobial Products, emphasized in a statement that “ensuring access to effective post-exposure prophylaxis remains a critical public health priority.” The approval comes as the World Health Organization (WHO) continues to monitor the spread of SARS-CoV-2 variants, including XBB.1.5 and its descendants, which have shown increased immune evasion. Ensitrelvir’s mechanism of action may offer advantages over existing drugs like Paxlovid, which has faced challenges with drug interactions and resistance.

How Ensitrelvir Works and Who It’s For

Ensitrelvir is designed to be taken as a five-day oral regimen, with doses adjusted based on age and weight. Clinical trials included participants with underlying medical conditions—such as obesity, diabetes, or cardiovascular disease—that place them at higher risk of severe COVID-19 outcomes. The FDA’s approval is based on Phase 3 trial data involving over 2,200 participants, with no new safety concerns identified beyond those observed in earlier studies, including mild gastrointestinal side effects like nausea or diarrhea.

Who qualifies for ensitrelvir? The drug is intended for:

• Adults and children aged 12+ weighing ≥40 kg who have been exposed to someone with confirmed COVID-19.
• Individuals with high-risk medical conditions, including but not limited to:
  • Obesity (BMI ≥30)
  • Type 2 diabetes or uncontrolled diabetes
  • Immunosuppressive disease or therapy
  • Chronic kidney disease
  • Severe obesity or cardiovascular disease
• Those who cannot receive a COVID-19 vaccine due to allergies or medical contraindications.

Unlike Paxlovid, which requires a prescription and is often limited by pharmacy availability, ensitrelvir’s approval may ease access challenges. However, the drug is not intended for treatment of active infection—only for prevention after exposure. The FDA has not yet approved it for pre-exposure prophylaxis (PrEP) or as a standalone therapy for hospitalized patients.

Comparing Ensitrelvir to Existing Antivirals

One notable advantage of ensitrelvir is its lower risk of drug interactions compared to Paxlovid, which relies on ritonavir—a potent cytochrome P450 inhibitor that can affect medications for heart disease, HIV, and immunosuppression. This may make ensitrelvir a preferable option for patients on complex regimens. However, the drug’s efficacy against newer variants remains under study, as emerging data suggests some variants may partially evade protease inhibitors.

Global Implications and Accessibility

The FDA’s approval of ensitrelvir could have ripple effects worldwide, particularly in regions where Paxlovid’s supply chain has been disrupted. Shionogi has already begun discussions with global regulators, including the European Medicines Agency (EMA), which is reviewing the drug under its conditional marketing authorization pathway. If approved in the EU, ensitrelvir could become available in member states as early as mid-2025, pending pricing negotiations.

Cost remains a critical factor. While Paxlovid’s price in the U.S. Has dropped to around $53 per course (subsidized by federal programs), ensitrelvir’s pricing strategy is still under development. Shionogi has not disclosed a final wholesale price, but industry analysts project it may range between $60–$100 per course, depending on production scale and patent protections. The company has also expressed interest in tiered pricing for low- and middle-income countries, though details are pending.

Public health experts warn that while ensitrelvir is a valuable addition, it should not replace vaccination and ventilation strategies. “Antivirals are a tool, not a substitute for primary prevention,” said Dr. Eric Topol, founder of the Scripps Research Translational Institute. “The best way to reduce post-exposure risk is still vaccination, followed by rapid testing and isolation.”

What Happens Next?

The FDA’s decision triggers several immediate steps:

1. Manufacturing and distribution: Shionogi must now scale production to meet projected demand, with the first shipments expected in Q1 2025 for U.S. Pharmacies and hospitals.
2. Global regulatory submissions: The EMA’s review is underway, with a Committee for Medicinal Products for Human Use (CHMP) opinion expected by June 2025. Other agencies, including Health Canada and Japan’s Pharmaceuticals and Medical Devices Agency (PMDA), are also evaluating the data.
3. Clinical monitoring: The FDA will require Shionogi to conduct post-marketing surveillance to assess long-term safety and efficacy, particularly in vulnerable populations like the elderly and immunocompromised.
4. Public health guidance: The CDC is expected to update its post-exposure prophylaxis recommendations within 30 days, clarifying eligibility and dosing for healthcare providers.